Mutations in SARS-CoV-2 are on the increase against the acquired immunity.

ABSTRACT

Monovalent vaccines using mRNA or adenoviruses have provided substantial protection against the COVID-19 pandemic in many countries. However, viral mutations have hampered the efficacy of this approach. The Omicron variant, which appeared in Dec 2021, has caused a pandemic that has exerted pressure on the healthcare system worldwide. The COVID-19 vaccines are not very effective against this variant, resulting in an increased rate of infection and mortality. Owing to the rapidly increasing number of patients, few countries, such as Australia, New Zealand, and Taiwan, which aimed at zero-COVID cases, have discontinued their attempts to contain the spread of infection by imposing strict lockdowns, for example. Therefore, the administration of booster vaccinations has been initiated; however, there are concerns about their effectiveness, sustainability, and possible dangers. There is also the question of how a variant with such isolated mutations originated and whether this is likely to continue in the future. Here, we compare the mutations in the Omicron variant with others by direct PCA to consider questions pertaining to their evolution and characterisation. The Omicron variant, like the other variants, has mutated in humans. The accumulated mutations overwhelmed the acquired immunity and caused a pandemic. Similar mutations are likely to occur in the future. Additionally, the variants infecting animals were investigated; they rapidly mutated in animals and varied from the human strains. These animal-adapted strains are probably not highly infectious or pathogenic to humans. Hence, the possibility of using these strains as vaccines will be discussed.